Jeanette E. Eckel‐Passow

Mayo Clinic — United States

Medicine · Health Sciences

50h-index11.0kcitations413works1.72yr avg

OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(117), Cancer Genomics and Diagnostics(51), Renal cell carcinoma treatment(45), Radiomics and Machine Learning in Medical Imaging(33), Epigenetics and DNA Methylation(31)

Publications409 total

Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, <i>IDH</i> -wildtype

Neuro-Oncology Advances·2025Open Access

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts

Neuro-Oncology Advances·2025Open Access

BIOM-64. ALTERATIONS IN MDM2/4-TP53 AXIS PREDICT RESPONSE TO TUMOR TREATING FIELD (TTF) THERAPY IN IDH WILD TYPE GLIOBLASTOMA

Neuro-Oncology·2025Open Access

PATH-82. Multivariate survival risk stratification in GBMs lacking necrosis and microvascular proliferation

Neuro-Oncology·2025Open Access

EPCO-33. MOLECULAR MARKERS OF CHROMOSOMAL INSTABILITY, INCLUDING COPY NUMBER VARIATION AND MDM2/4 AMPLIFICATION, ARE PROGNOSTIC IN IDH WILD TYPE GLIOBLASTOMA

Neuro-Oncology·2025Open Access

PATH-36. DNA copy number clustering reveals alterations that influence survival in primary IDH-mutant astrocytoma patients

Neuro-Oncology·2025Open Access

EPCO-26. HIGH-RESOLUTION PROFILING OF TELOMERE DYNAMICS AND GENOMIC VARIANTS IN ASTROCYTOMAS USING LONG-READ SEQUENCING

Neuro-Oncology·2025Open Access

NODG-01 EVALUATING THE CURRENT NEURO-ONCOLOGY CAPACITY IN SUB-SAHARAN AFRICA: A QUESTIONNAIRE-BASED SURVEY

Neuro-Oncology Advances·2025Open Access

BIOM-30. LONGITUDINAL CEREBROSPINAL FLUID D-2-HYDROXYGLUTARATE FOR DISEASE MONITORING IN PATIENTS WITH IDH-MUTANT GLIOMAS

Neuro-Oncology·2025

IMG-38. Differentiating adult diffuse IDH-mutant glioma from molecular glioblastoma IDH-wildtype using deep learning on MRI

Neuro-Oncology·2025Open Access

IMG-87. Differentiation of IDH-Wildtype Glioblastoma and Primary Central Nervous System Lymphoma Using 3D Deep Learning on MRI

Neuro-Oncology·2025Open Access

Abstract B090: Radiation-induced oral mucositis to rapidly determine effective radiosensitizing dosing regimens for ATM and DNAPK inhibitors

Molecular Cancer Therapeutics·2025

Discovery and Validation of Molecular Biomarkers for Differentiation of Nondysplastic Barrett’s Esophagus from High-grade Dysplasia and Esophageal Adenocarcinoma

1 cited

Cancer Prevention Research·2025· 1 citedOpen Access

Data from Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

2025Open Access

Supplementary Data1 from Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

2025Open Access

Genomewide association study of a homogeneous multiple sclerosis cohort: Tumefactive demyelination

Multiple Sclerosis Journal·2025Open Access

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

1 cited

Clinical Cancer Research·2025· 1 citedOpen Access

Supplemental Figure 1 from DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits

2025Open Access

Supplemental Figure 3 from DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits

2025Open Access

Supplemental Figure 2 from DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits

2025Open Access

page 1 of 21Next →